Intracellular pathways involved in cell survival are deregulated in mouse and human spinal muscular atrophy motoneurons

Other authors

Institut Català de la Salut

[Sansa A, de la Fuente S, Garcera A, Soler RM] Neuronal Signaling Unit, Experimental Medicine Department, Universitat de Lleida-IRBLleida, 25198, Lleida, Spain. [Comella JX] CIBERNED & Grup de Senyalització Cel·lular i Apoptosi, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2022-03-21T09:08:30Z

2022-03-21T09:08:30Z

2021-07



Abstract

Apoptosi; Motoneurones; Atròfia muscular espinal


Apoptosis; Motoneuronas; Atrofia muscular espinal


Apoptosis; Motoneurons; Spinal muscular atrophy


Spinal Muscular Atrophy (SMA) is a severe neuromuscular disorder caused by loss of the Survival Motor Neuron 1 gene (SMN1). Due to this depletion of the survival motor neuron (SMN) protein, the disease is characterized by the degeneration of spinal cord motoneurons (MNs), progressive muscular atrophy, and weakness. Nevertheless, the ultimate cellular and molecular mechanisms leading to cell loss in SMN-reduced MNs are only partially known. We have investigated the activation of apoptotic and neuronal survival pathways in several models of SMA cells. Even though the antiapoptotic proteins FAIM-L and XIAP were increased in SMA MNs, the apoptosis executioner cleaved-caspase-3 was also elevated in these cells, suggesting the activation of the apoptosis process. Analysis of the survival pathway PI3K/Akt showed that Akt phosphorylation was reduced in SMA MNs and pharmacological inhibition of PI3K diminished SMN and Gemin2 at transcriptional level in control MNs. In contrast, ERK phosphorylation was increased in cultured mouse and human SMA MNs. Our observations suggest that apoptosis is activated in SMA MNs and that Akt phosphorylation reduction may control cell degeneration, thereby regulating the transcription of Smn and other genes related to SMN function.


This work was supported by grants from Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias, Unión Europea, Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa” (PI17/00231 and PI20/00098) to RMS and AG; CERCA Program/Generalitat de Catalunya; and Spanish Agency of Research (Agencia Estatal de Investigacion-PID2019-107286RB-I00) and CIBERNED to JXC. AS holds a fellowship from Universitat de Lleida and SdF holds a fellowship from “Ajuts de Promoció de la Recerca en Salut” (IRBLleida-Diputació de Lleida). We thank Elaine Lilly, PhD, for English language revision of the paper.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

Neurobiology of Disease;155

https://doi.org/10.1016/j.nbd.2021.105366

info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-107286RB-I00

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)